Could a peptide injection help rebuild Insulin-Making cells?

NCT ID NCT02538848

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called HTD4010, a synthetic version of a natural peptide that may help the pancreas regenerate insulin-producing cells. The study enrolls healthy, non-diabetic volunteers to receive single ascending doses of the drug or a placebo. The main goal is to assess how safe and tolerable the drug is, and how the body processes it, before any potential future studies in people with type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HTD4010, an experimental injectable analog of the INGAP peptide
What this could lead to
If safe and well-tolerated, HTD4010 could pave the way for future studies exploring its potential to help regenerate insulin-producing cells, possibly offering a new approach to treating type 2 diabetes.
What could go wrong
This is an early, first-in-human study focused on safety, not effectiveness. The drug may cause unexpected side effects or fail to show promise in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Linear Clinical Research Limited

    Perth, WA6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.